Our mission is to accelerate the translation of world-class research discoveries to optimal care for breast cancer patients
TransBCR supports three complimentary research platforms
Clinical trials of targeted therapies in breast cancer, including early Phase 0, I and II studies, encompassing breast cancer prevention, neo-adjuvant therapy, and treatment of advanced disease.
These studies will enable innovative Phase III trials that require companion biomarker evaluation.
Breast Biomarker Program
The Breast Biomarker Program coordinates the prospective collection and testing of tumour and normal breast tissue samples for different research projects.
These samples may be evaluated for molecular markers to guide patient selection for suitable clinical trials and therapy.
Ductal Carcinoma In Situ (DCIS) is a type of pre-invasive breast cancer.
This project aims to build a bank of highly annotated DCIS tissue samples for biomarker research.